BBB-Selective Antibodies for Receptor-Mediated Brain Uptake
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for targeting the blood-brain barrier (BBB) with antibodies are inefficient and non-specific, leading to limited brain uptake and potential off-target effects, with in vivo and in vitro screening techniques yielding limited success in identifying effective antibody-receptor-mediated transport (RMT) pairs.
Innovation Solution
Development of BBB-selective antibodies and antigen-binding fragments with specific CDR sequences (e.g., SEQ ID NOs) that target BBB receptors, identified through a phenotypic screening method using human induced pluripotent stem cell-derived brain microvascular endothelial cells, demonstrating binding and transcytosis across the BBB.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If existing antibody targeting methods are used to cross the blood-brain barrier, then some level of brain uptake is achieved, but the uptake is limited to approximately 0.1% of circulating antibody levels and exhibits non-specific off-target effects
Solution Approach 1:
The patent applies parameter changes by modifying the antibody structure through CDR region engineering to achieve high-specificity binding to BBB receptors. The identified CDR sequences (e.g., CDRH1: GFTFSGYW, CDRH2: IKGDGTDI, CDRH3: ARDLRQTHWFDS) represent specific parameter changes in the antibody's binding regions that enable selective recognition of brain endothelial cell receptors, thereby improving both brain uptake quantity and targeting specificity simultaneously
Solution Approach 2:
The patent employs copying by creating highly specific antibody clones that replicate the ideal binding characteristics needed for BBB penetration. Through phenotypic screening, specific antibody clones with optimal CDR sequences were copied and selected, achieving consistent high-affinity binding to BBB receptors. This copying approach allows replication of the most effective binding parameters across multiple antibody molecules, ensuring reliable and specific brain targeting
2Adaptability or versatility
If phenotypic screening of large antibody libraries is performed to identify new BBB RMT pairs, then potential new targets can be discovered, but the success rate is limited with only a handful of new BBB targeting antibodies isolated
Solution Approach 1:
The patent applies taking out by extracting the essential binding characteristics from successful antibody clones and isolating their CDR sequences. By extracting the critical CDR regions (CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, CDRL3) from high-performing antibodies, the patent creates a focused set of binding parameters that can be systematically applied. This extraction approach converts the complexity of whole-antibody screening into a more manageable CDR sequence optimization problem, improving productivity in discovering new BBB-targeting antibodies
Solution Approach 2:
The patent demonstrates universality by showing that the identified CDR sequences can be applied across different antibody frameworks and potentially target multiple BBB receptors. The CDR regions represent universal binding elements that can be transferred between different antibody molecules, enabling a single set of CDR sequences to function in multiple antibody contexts. This multi-functionality increases the productivity of antibody discovery by allowing one successful CDR set to generate multiple viable BBB-targeting antibodies
3Reliability
If in vivo screening with phage antibody libraries is performed, then potential BBB-targeting antibodies can be identified, but high background recoveries mask relevant clones
Solution Approach 1:
The patent applies local quality by focusing the screening effort on specific local regions of the antibody structure—the CDR regions—rather than evaluating entire antibodies. By concentrating the detection and selection process on the localized CDR sequences that directly interact with BBB receptors, the patent improves the signal-to-noise ratio. This local quality approach allows relevant clones to be identified based on their specific CDR binding characteristics, masking less from the high background recoveries that plague whole-antibody screening
4Ease of manufacture
If in vitro biopanning is used to identify BBB-targeting antibodies, then potential candidates can be screened, but the identified antibodies often do not cross-react with in vivo antigens due to altered protein expression profiles in culture
Solution Approach 1:
The patent applies preliminary action by performing phenotypic screening under conditions that pre-establish the correct protein expression profiles before final antibody selection. The screening process is designed to occur in an environment that mimics in vivo conditions, ensuring that BBB receptors are expressed correctly before antibodies are selected. This preliminary establishment of proper expression profiles ensures that antibodies selected in vitro will maintain their cross-reactivity with in vivo antigens, resolving the reliability issue
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The developed antibodies exhibit enhanced brain accumulation and specificity, with one clone showing a 26-fold increase in brain uptake, suggesting potential for effective CNS therapeutic delivery.
Implementation Method 1
a host of molecular transporters are expressed by BMECs that allow the selective passage of necessary nutrients across the BMECs by carrier-mediated and receptor-mediated transport (RMT) mechanisms
Implementation Method 2
trigger transcytosis of the targeting antibody and any attached therapeutic cargo across the BMECs and into the brain
Data Source
AI summary
The present invention provides antibodies or antigen-binding fragments thereof including single chain variable fragment (scFv) antibodies that specifically bind to and translocate the blood-brain barrier and methods of use.